Navigation Links
Glimepiride in the medical management of Type 2 diabetes

Type 2 diabetes mellitus, a disorder of impaired insulin secretion and insulin resistance, has reached epidemic proportions.// The identification of high-risk individuals and lifestyle management can help control diabetes; however, most patients require pharmacologic intervention.

To achieve glycemic control, a stepwise treatment approach has generally been used, beginning with a program of diet and exercise, and to minimize the risk of future micro- and macrovascular complications.

Oral agents, with or without insulin, are added when diet and exercise fail to normalize glucose levels. Various pharmacologic agents are available for the management of Type 2 diabetes, including first- and second-generation sulfonylureas (glimepiride, glipizide, and glyburide), biguanides (metformin), á-glucosidase inhibitors (acarbose and miglitol), thiazolidinediones (pioglitazone and rosiglitazone), meglitinide analogues (repaglinide), amino acid D-phenylalanine derivatives (nateglinide), and insulin.

A recent article, presented in vol 18 (6) of Journal of Diabetes and its Complications reviews the role of the sulfonylureas - with a major focus on glimepiride, the newest of the second-generation sulfonylureas - in the medical management of Type 2 diabetes.

The sulfonylureas, the first oral agents introduced for the management of Type 2 diabetes, are effective, well-tolerated, and well-established drugs; Second-generation sulfonylureas are now widely used in the management of Type 2 diabetes. The most recent addition, glimepiride, can be used in combination with metformin, the thiazolidinediones, a-glucosidase inhibitors, and insulin. The unique properties of glimepiride may provide advantages over other currently available insulin secretagogues.

Type 2 diabetes mellitus can lead to serious long-term sequelae, such as blindness, kidney failure, heart disease, neurologic impairment, and stroke. Stringent lifestyle modifications, in cluding diet and exercise, are important measures in diabetes management, but they are often not sufficient to control hepatic glucose output and hyperglycemia.

The author, Stephen N. Davis, stresses that it is important to treat patients to the established target values for blood glucose and A1C to achieve and maintain normal glucose physiology.

Sulfonylureas are effective, well-tolerated drugs that have been used for decades. However, many of the original second-generation sulfonylureas are associated with hypoglycemia and weight gain and thus may not be appropriate for patients prone to hypoglycemia or for those who are overweight or renally impaired.

The investigation of glimepiride, the newest second-generation sulfonylurea, has led to the identification of several properties that may overcome some of these limitations. In addition, glimepiride has been found to effectively reduce PPG and FPG levels and A1C concentrations and has a good safety profile.

Medindia on Diabetes: Diabetes is a group of diseases with one thing in common - a problem with insulin. The problem could be that your body doesn't make any insulin, doesn't make enough insulin or doesn't use insulin properly.
'"/>




Related medicine news :

1. Check if your “Favourite medical web-site” is indulging in Quackey
2. Teens turning to Internet for medical queries
3. Robots craft medical history
4. NBE to conduct test for medical students from abroad
5. Air pollution combined with greater medical needs
6. Children! Protecting them from medical mistakes
7. More information sought by patients on medical errors
8. SARS necessitates medical masks
9. Mini motor for micromedical applications
10. Avenues to opened for medical tourists following relaxation of visa regulations
11. Canadians flocking to India for quick and efficient medical treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/3/2016)... ... May 03, 2016 , ... The new ... medium and small physician practices, to better grasp and implement HIPAA’s privacy, security, ... guides practices on a well-defined, expert-created path to compliance. HIPAA Institute has positioned ...
(Date:5/2/2016)... ... May 03, 2016 , ... RNK ... sSOIP telemedicine stethoscope software that enables the stethoscope stream to go over the ... works with RNK’s flagship PCP-USB stethoscope. , Remote auscultation involves two software elements ...
(Date:5/2/2016)... Texas (PRWEB) , ... May 02, 2016 , ... ... 3, Issue 1 of Patient Experience Journal (PXJ), an international, open access, ... experience. With almost half the issue representing international (non-US) based authors, the third ...
(Date:5/2/2016)... Texas (PRWEB) , ... May 02, 2016 , ... The ... a time to honor the civilian nurses that care for its uniformed service members, ... signed a proclamation in 1974 designating May 6th through May 12th National Nurses Week. ...
(Date:5/2/2016)... ... May 02, 2016 , ... In honor of National Physical Fitness and ... people who share their fitness journey on social media. , The foot care ... award a $100 product voucher each week during May to one winner. , “Whether ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, ... Lifecycle Management Solutions (VLMS) today announced that ... services for sufferers of chronic kidney failure ... to manage their corporate validation process. The ... a software solution to manage their validation ...
(Date:4/28/2016)... PUNE, India , April 28, 2016 /PRNewswire/ ... - Pipeline Review, H1 2016" is a report ... pipeline and helps strengthen R&D pipelines by identifying ... best-in-class products. Company Profiles discussed in ... Menarini Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen ...
Breaking Medicine Technology: